356 related articles for article (PubMed ID: 27181836)
1. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
2. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
[TBL] [Abstract][Full Text] [Related]
3. Ritonavir nanosuspensions prepared by microfluidization with enhanced solubility and desirable immunological properties.
Karakucuk A; Canpinar H; Celebi N
Pharm Dev Technol; 2022 Dec; 27(10):1027-1037. PubMed ID: 36343117
[TBL] [Abstract][Full Text] [Related]
4. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of improved oral bioavailability of ritonavir nanosuspension.
Karakucuk A; Teksin ZS; Eroglu H; Celebi N
Eur J Pharm Sci; 2019 Apr; 131():153-158. PubMed ID: 30790704
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
7. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
8. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
9. Isoliquiritigenin Nanosuspension Enhances Cytostatic Effects in A549 Lung Cancer Cells.
Qiao F; Zhao Y; Mai Y; Guo J; Dong L; Zhang W; Yang J
Planta Med; 2020 May; 86(8):538-547. PubMed ID: 32294789
[TBL] [Abstract][Full Text] [Related]
10. A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation.
Pınar SG; Canpınar H; Tan Ç; Çelebi N
Eur J Pharm Sci; 2022 Apr; 171():106123. PubMed ID: 35017012
[TBL] [Abstract][Full Text] [Related]
11. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
12. Investigation of Formulation and Process Parameters of Wet Media Milling to Develop Etodolac Nanosuspensions.
Karakucuk A; Celebi N
Pharm Res; 2020 May; 37(6):111. PubMed ID: 32476048
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders.
Du B; Li XT; Zhao Y; A YM; Zhang ZZ
Pharmazie; 2010 Jul; 65(7):471-6. PubMed ID: 20662313
[TBL] [Abstract][Full Text] [Related]
14. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
Freag MS; Elnaggar YS; Abdallah OY
Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
[TBL] [Abstract][Full Text] [Related]
15. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions.
Pu X; Sun J; Wang Y; Wang Y; Liu X; Zhang P; Tang X; Pan W; Han J; He Z
Int J Pharm; 2009 Sep; 379(1):167-73. PubMed ID: 19505545
[TBL] [Abstract][Full Text] [Related]
16. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
17. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
[TBL] [Abstract][Full Text] [Related]
18. Nanosuspension for parenteral delivery of a p-terphenyl derivative: preparation, characteristics and pharmacokinetic studies.
Tian X; Li H; Zhang D; Liu G; Jia L; Zheng D; Shen J; Shen Y; Zhang Q
Colloids Surf B Biointerfaces; 2013 Aug; 108():29-33. PubMed ID: 23528604
[TBL] [Abstract][Full Text] [Related]
19. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
20. Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach.
Mohapatra PK; Srivastava R; Varshney KK; Babu SH
Anticancer Agents Med Chem; 2022; 22(10):1984-2001. PubMed ID: 34353274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
